HRQoL of European children and adolescents with short stature as assessed with generic (KIDSCREEN) and chronic-generic (DISABKIDS) instruments

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):817-27. doi: 10.1586/14737167.2013.847366.

Abstract

Short stature may be associated with impairments in health-related quality of life (HRQoL). This study compared the HRQoL of children/adolescents diagnosed with short stature to population norms and examined the effects of height deviation and treatment status on HRQoL.

Method: We cross-sectionally assessed 110 children/adolescents aged 8-18, with current short stature (height deviation ≤-2 standard-deviation (SD)) or normal height achieved since diagnosis, and 98 parents, using the generic KIDSCREEN and the chronic-generic DISABKIDS instruments.

Results: Generic HRQoL of patients was similar to population norms. Patients with achieved normal height reported better chronic-generic HRQoL when untreated, while patients with current short stature reported better HRQoL upon receiving treatment. Parents reported better HRQoL for treated patients, especially for girls.

Conclusion: Although their HRQoL is not significantly compromised, patients diagnosed with short stature may profit from growth-hormone treatment. Specific instruments are needed to adequately assess the effectiveness of treatment.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Body Height*
  • Child
  • Cross-Sectional Studies
  • Europe
  • Female
  • Growth Disorders / drug therapy
  • Human Growth Hormone / therapeutic use
  • Humans
  • Male
  • Quality of Life*
  • Surveys and Questionnaires*

Substances

  • Human Growth Hormone